Neoadjuvant Checkpoint Inhibitors with Chemotherapy Improve Outcomes in Early Triple‑Negative and PD‑L1+ HR‑Positive Breast Cancer — A Critical Appraisal of Recent Meta‑Analysis

Highlights

– Neoadjuvant immune checkpoint inhibitors (ICIs) added to chemotherapy increased pathologic complete response (pCR) rates in triple‑negative breast cancer (TNBC) irrespective of PD‑L1 status, with absolute pCR improvements of >10%.

– In hormone receptor–positive/ERBB2‑negative (HR+/ERBB2‑) disease, pCR benefit was confined to the PD‑L1–positive subgroup (absolute improvement +12.2%); no pCR benefit was observed in ERBB2‑positive tumors.